⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 14, 2024Open Access

Figure 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Rémi Vernet Eugenio Fernández Denis Migliorini Virginie Ancrenaz Emily Charrier Marie‐Claude Belkouch Olivier Von Rohr Muriel Urwyler Claudio De Vito Jessica Renaux Jean Villard Olivier Rubin Julien Grogg Nicolas Mach

View Full Paper

Ask AI

Bookmark

Share

Abstract

Swimmer plot showing OS of each patient since the start of MVX-ONCO-1 treatment. *, Number of patients who have theoretically reached the time point of interest at the cutoff date. Patients lost to follow-up are included.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vernet et al. (2024) studied this question.

synapsesocial.com/papers/68e5c62db6db64358755d2a9 https://doi.org/10.1158/2767-9764.26644220.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
2Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024 · 1 citations
3Figure 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
4Figure 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
5Figure 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024

Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024